Red Light Therapy Hair Growth: Clinical Trial Evidence

Red light therapy — more precisely, low-level laser therapy (LLLT) or photobiomodulation (PBM) — is one of the few hair loss interventions with both an FDA clearance and a growing body of randomised controlled trial evidence. Multiple clinical trials have demonstrated statistically significant increases in hair density and hair count following red or near-infrared light exposure to the scalp.

This article examines the key clinical trials in detail: their methodologies, results, limitations, and what the evidence actually tells us about using light therapy for hair regrowth. No marketing spin — just the published data.

The Biological Mechanism

Before examining individual trials, it helps to understand why light therapy might stimulate hair growth at all.

Hair follicles cycle through anagen (growth), catagen (regression), and telogen (resting) phases. In androgenetic alopecia (AGA), the most common form of hair loss, follicles progressively miniaturise — anagen phases shorten while telogen phases lengthen. The result is thinner, shorter hairs that eventually become invisible.

Photobiomodulation is thought to influence hair growth through several pathways:

Cytochrome c oxidase absorption. Red light (630-670nm) and near-infrared light (810-850nm) are absorbed by cytochrome c oxidase in the mitochondrial electron transport chain. This increases ATP production, which may provide energy for metabolically active follicular cells during anagen (Karu, 2010).

Nitric oxide release. Light absorption dissociates nitric oxide from cytochrome c oxidase, increasing local NO availability. Nitric oxide is a potent vasodilator — improved blood flow to the dermal papilla may enhance nutrient delivery to follicles (Hamblin, 2017).

Wnt/beta-catenin signalling. Animal studies suggest that PBM may upregulate the Wnt/beta-catenin pathway, which plays a critical role in hair follicle development and cycling (Liao et al., 2014). This could potentially shift follicles from telogen back into anagen.

Anti-inflammatory effects. Perifollicular inflammation (microinflammation) is increasingly recognised as a contributor to AGA progression. PBM’s established anti-inflammatory properties may help create a more favourable environment for hair growth (Mahdi et al., 2019).

Key Randomised Controlled Trials

Lanzafame et al. (2014) — Male Androgenetic Alopecia

Citation: Lanzafame, R.J., Blanche, R.R., Bodian, A.B., et al. (2014). The growth of human scalp hair mediated by visible red light laser and LED sources in males. Lasers in Surgery and Medicine, 46(5), 373-377.

Design: Double-blind, sham-device-controlled RCT. 44 males with Norwood-Hamilton IIa-V androgenetic alopecia, aged 18-48. Treatment group received 655nm laser light via a helmet device; control group received a visually identical sham device.

Protocol: Every other day for 16 weeks. Each session lasted approximately 25 minutes.

Results: The treatment group showed a 39% increase in hair count compared to baseline, versus a 2% increase in the sham group. This difference was statistically significant (p < 0.001). Hair density improvements were most pronounced in the vertex region.

Strengths: Proper blinding with sham device. Standardised measurement methodology using macrophotography at tattooed reference points. Adequate follow-up period.

Limitations: Relatively small sample size (22 per group). Single wavelength tested. No long-term follow-up beyond 16 weeks — we don’t know whether gains were maintained after treatment cessation. The study was industry-funded (Apira Science), which manufactured the device used.

Lanzafame et al. (2014) — Female Pattern Hair Loss

Citation: Lanzafame, R.J., Blanche, R.R., Chiacchierini, R.P., et al. (2014). The growth of human scalp hair in females using visible red light laser and LED sources. Lasers in Surgery and Medicine, 46(8), 601-607.

Design: Double-blind, sham-controlled RCT. 47 females with Ludwig-Savin I-II female pattern hair loss, aged 25-60. Same 655nm laser helmet device as the male study.

Protocol: Every other day for 16 weeks.

Results: Treatment group showed a 37% increase in hair count versus baseline. The sham group showed approximately 2% decrease. The difference was highly significant (p < 0.001).

Strengths: Addressed female pattern hair loss specifically, which is underrepresented in hair loss research. Same rigorous blinding and measurement protocol as the male study.

Limitations: Same limitations as the male study — industry funding, short follow-up, single wavelength. Female pattern hair loss differs mechanistically from male AGA, so the similar response rate is noteworthy but the biological explanation may differ.

Jimenez et al. (2014) — HairMax LaserComb Trials

Citation: Jimenez, J.J., Wikramanayake, T.C., Bergfeld, W., et al. (2014). Efficacy and safety of a low-level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device-controlled, double-blind study. American Journal of Clinical Dermatology, 15(2), 115-127.

Design: Multicentre, randomised, double-blind, sham-controlled trial. 128 males and 141 females with AGA. Three different HairMax LaserComb models tested (7-beam, 9-beam, and 12-beam), each against a matched sham device. Wavelength: 655nm.

Protocol: Three times per week for 26 weeks.

Results: All three laser devices produced statistically significant increases in terminal hair density compared to sham devices. The 12-beam device showed the greatest improvement: males gained an average of 20.2 hairs/cm² versus 2.8 hairs/cm² in the sham group; females gained 20.6 hairs/cm² versus 3.0 in sham.

Strengths: This is the largest RCT in the LLLT-for-hair-loss literature to date. Multicentre design reduces site-specific bias. Longer treatment period (26 weeks) than the Lanzafame studies. Testing multiple beam configurations provides dose-response information.

Limitations: Industry-funded (Lexington International). The comb form factor means treatment is manual and technique-dependent — coverage consistency varies between users. No assessment of hair thickness or quality beyond density counts. No post-treatment follow-up to assess durability.

Kim et al. (2013) — 630nm vs 830nm

Citation: Kim, H., Choi, J.W., Kim, J.Y., et al. (2013). Low-level light therapy for androgenetic alopecia: a 24-week, randomized, double-blind, sham device-controlled multicenter trial. Dermatologic Surgery, 39(8), 1177-1183.

Design: Multicentre, randomised, double-blind, sham-controlled RCT. 40 subjects with AGA (both male and female). Treatment device emitted a combination of 630nm and 830nm LEDs.

Protocol: Daily use for 24 weeks using a helmet-style device. Sessions lasted 18 minutes.

Results: The treatment group showed a significant increase in hair density (p = 0.003) and hair thickness (p = 0.03) compared to sham. Notably, this study measured hair thickness in addition to count — an important quality measure that most LLLT trials omit.

Strengths: Combined red and near-infrared wavelengths, which more closely mirrors modern consumer devices. Measured both density and thickness. Daily protocol provides data on a higher-frequency treatment regimen.

Limitations: Small sample size. Mixed male and female cohort without subgroup analysis. The combined wavelength approach means we can’t isolate the contribution of each wavelength.

Afifi et al. (2017) — Systematic Review and Meta-Analysis

Citation: Afifi, L., Maranda, E.L., Zarei, M., et al. (2017). Low-level laser therapy as a treatment for androgenetic alopecia. Lasers in Surgery and Medicine, 49(1), 27-39.

Design: Systematic review and meta-analysis of 11 studies (including all the above trials). Pooled data from RCTs investigating LLLT for AGA.

Key findings: Across all analysed studies, LLLT produced a statistically significant increase in hair density compared to sham treatment. The pooled mean difference was approximately 17.2 hairs/cm² in favour of LLLT. The evidence was strongest for 655nm wavelength devices used 3-7 times per week over 16-26 weeks.

Important caveats from the review: The authors noted high heterogeneity between studies (different devices, protocols, measurement methods), limited long-term data, and the predominance of industry-funded trials. They concluded that while LLLT shows promise, more independent, longer-term studies are needed.

What the Evidence Actually Proves

Let’s be precise about what these trials demonstrate and what they don’t.

What’s established:

• Red light at 630-660nm and near-infrared at 810-850nm can increase hair count and density in people with mild to moderate androgenetic alopecia.
• Effects are statistically significant compared to sham devices across multiple independent RCTs.
• Both male and female pattern hair loss respond to treatment.
• The treatment appears safe — no serious adverse events were reported in any trial.

What’s not established:

• Whether results are maintained long-term without continued treatment. No trial has followed subjects beyond 26 weeks, and none has tracked what happens after treatment stops.
• Whether LLLT works for advanced hair loss (Norwood VI-VII or Ludwig III). Trials focused on mild to moderate cases.
• The optimal protocol. Studies used different frequencies (daily, every other day, three times weekly), different session durations, and different total treatment periods. We don’t know the minimum effective dose.
• Whether LLLT can regrow hair on completely bald scalp. The evidence suggests it strengthens and thickens miniaturising follicles rather than resurrecting dead ones.
• How LLLT compares head-to-head with minoxidil or finasteride. No direct comparison RCTs exist.

Effective Parameters Based on Clinical Data

Synthesising across the published trials, the following parameters have the strongest evidence base:

Parameter	Evidence-Supported Range
Wavelength	630-660nm (red) or 810-850nm (NIR), or combination
Irradiance at scalp	20-60 mW/cm²
Session duration	15-25 minutes
Frequency	3-7 times per week
Minimum treatment period	16 weeks before assessing results
Energy density (fluence)	1-4 J/cm² per session

The most commonly used and best-evidenced wavelength is 655nm. However, combination devices using both red and near-infrared wavelengths (such as in the Kim 2013 trial) may offer advantages by targeting different tissue depths — red light for the superficial follicular epithelium and NIR for the deeper dermal papilla.

Male vs Female Pattern Hair Loss: Does Evidence Differ?

The Lanzafame group ran nearly identical trials in males and females and found comparable response rates (39% vs 37% increase in hair count). The Jimenez multicentre trial also showed similar magnitude improvements across sexes.

However, there are important distinctions:

Female pattern hair loss (FPHL) typically presents as diffuse thinning across the crown with preservation of the frontal hairline. The pathophysiology is less androgen-dependent than male AGA, and FPHL often involves factors like iron deficiency, thyroid dysfunction, and hormonal changes. LLLT’s mechanism of action — improving follicular metabolism and blood flow — may work regardless of the underlying cause of miniaturisation, which could explain why it shows efficacy in both sexes.

Male AGA involves a more defined pattern of recession and vertex thinning driven primarily by DHT-mediated follicular miniaturisation. LLLT does not block DHT, so it addresses the downstream effects (poor follicular metabolism, reduced blood flow) rather than the root cause. This may explain why LLLT alone is unlikely to halt progression in males with aggressive AGA — it may need to be combined with a DHT blocker for sustained results.

Combination therapy is where the practical interest lies, but the evidence is thin. A few small studies and case series suggest that LLLT combined with minoxidil or finasteride may produce additive effects, but no large RCTs have tested this directly. Anecdotally, many dermatologists recommend LLLT as an adjunct to pharmacotherapy rather than a standalone treatment.

Limitations of the Current Evidence Base

Transparency demands acknowledging the weaknesses in this field:

Industry funding dominates. Nearly every major LLLT-for-hair-loss RCT was funded by a device manufacturer. This doesn’t automatically invalidate results — sham-controlled designs with proper blinding are robust — but it means there may be unpublished negative trials (publication bias).

Short follow-up periods. The longest trial ran for 26 weeks. Hair loss is a chronic, progressive condition. We need 1-2 year data to understand whether LLLT provides lasting benefit or merely a temporary boost.

No standardised outcome measures. Studies use different counting methods, different reference areas, and different photography protocols. This makes cross-study comparison difficult and meta-analysis less reliable.

Narrow patient populations. Trials exclude advanced hair loss, alopecia areata, scarring alopecia, and chemotherapy-induced hair loss. The evidence applies specifically to mild-moderate AGA.

No dose-finding studies. We don’t have systematic dose-response data. The optimal wavelength, irradiance, session duration, and treatment frequency remain somewhat empirical.

The Bottom Line

The clinical trial evidence for red light therapy in hair growth is genuinely promising — more so than for many conditions where LLLT is marketed. Multiple sham-controlled RCTs consistently show statistically and clinically meaningful increases in hair density.

However, this is not a miracle cure. The evidence supports LLLT as a safe, modestly effective treatment for mild to moderate androgenetic alopecia in both men and women. Think of it as comparable in magnitude to minoxidil — a worthwhile tool, especially for people who can’t tolerate pharmacotherapy, but not a replacement for comprehensive hair loss management.

If you’re considering LLLT for hair loss, the evidence suggests: use a device delivering 630-660nm or 810-850nm at adequate irradiance, treat consistently for at least 16 weeks before judging results, and set realistic expectations. A 20-40% improvement in hair count is a reasonable hope based on the published data. Full regrowth of a bald scalp is not.

References

• Afifi, L., Maranda, E.L., Zarei, M., et al. (2017). Low-level laser therapy as a treatment for androgenetic alopecia. Lasers in Surgery and Medicine, 49(1), 27-39.
• Hamblin, M.R. (2017). Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophysics, 4(3), 337-361.
• Jimenez, J.J., Wikramanayake, T.C., Bergfeld, W., et al. (2014). Efficacy and safety of a low-level laser device in the treatment of male and female pattern hair loss. American Journal of Clinical Dermatology, 15(2), 115-127.
• Karu, T. (2010). Mitochondrial mechanisms of photobiomodulation in context of new data about multiple roles of ATP. Photomedicine and Laser Surgery, 28(2), 159-160.
• Kim, H., Choi, J.W., Kim, J.Y., et al. (2013). Low-level light therapy for androgenetic alopecia: a 24-week, randomized, double-blind, sham device-controlled multicenter trial. Dermatologic Surgery, 39(8), 1177-1183.
• Lanzafame, R.J., Blanche, R.R., Bodian, A.B., et al. (2014). The growth of human scalp hair mediated by visible red light laser and LED sources in males. Lasers in Surgery and Medicine, 46(5), 373-377.
• Lanzafame, R.J., Blanche, R.R., Chiacchierini, R.P., et al. (2014). The growth of human scalp hair in females using visible red light laser and LED sources. Lasers in Surgery and Medicine, 46(8), 601-607.
• Liao, X., Xie, G.H., Liu, H.W., et al. (2014). Helium-neon laser irradiation promotes the proliferation and migration of human epidermal stem cells in vitro: proposed mechanism for hair stimulation. Photomedicine and Laser Surgery, 32(2), 94-101.
• Mahdi, A.A., Ansari, J.A., Alzohairy, M.A., et al. (2019). Role of photobiomodulation in hair follicle biology. Lasers in Medical Science, 34(6), 1083-1095.